The ARAMIS (American Rheumatism Association Medical Information System) Post-Marketing Surveillance Program

Abstract

ARAMIS, the national arthritis data resource, tracks 22,000 patients from 17 centers by prospective protocol, recording all routine clinical data and with regular assessment of patient status including mortality, disability, discomfort, drug side effects, and economic impact. In the ARAMIS post-marketing surveillance program, these data are used to answer questions of (a) comparative toxicity between drugs, (b) long-term drug effects, (c) effects of drug combinations upon toxicity, (d) effects of comorbidity, (e) generalizability of pre-marketing estimates, and (f) clinical characteristics of those with side reactions. Differences found in specific toxicity, both clinical and laboratory, between different drugs and with drug combinations are important, and these differences had not been discoverable from pre-marketing studies.

Keywords

ARAMIS Data-bank Post-marketing surveillance Side-effect incidence Side-effect prevalence

Get full access to this article

View all access options for this article.

References

Fries

McShane

: ARAMIS: A national chronic disease data bank system, in Proceedings of the Third Annual Symposium on Computer Applications in Medical Care. IEEE, Washington, DC, October 1979, pp 798–801.

Fries

: Long-term outcome, long-term data, in Proceedings of the First Annual Conference of the American Association for Medical Systems and Informatics. Washington, DC, October 1982, vol 1, pp 10–11.

Fries

Hess

Klinenberg

: A uniform database for rheumatic diseases. Arth Rheum 1979; 22: 1029–1033.

Fries

: ARAMIS: A national arthritis data resource, in Proceedings from the Fourth International Conference on Epidemiology of the Rheumatic Diseases. U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, Maryland, September 1980, pp 54–1–54–8.

Fries

: The chronic disease data bank: First principles to future directions. J Philos Med 1984; 9: 161–180.

Fries

Spitz

Kraines

Holman

: Measurement of patient outcome in arthritis. Arth Rheum 1983; 23: 137–145.

Fries

Spitz

Young

: The dimensions of health outcomes: The health assessment questionnaire, disability and pain scales. J Rheum 1982; 9: 789–793.

Fries

: Toward an understanding of patient outcome assessment. Arth Rheum 1983; 26: 697–704.

Coles

Fries

Kraines

Roth

: From experiment to experience: Side effects of non-steroidal anti-inflammatory drugs. Amer J Med 1983; 74: 820–828.

10.

Wasner

Britton

Kraines

Kaye

Bobrove

Fries

: Non-steroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis. JAMA 1983; 246: 2168–2172.